Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Company profile

TYME stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


10 Aug 21
20 Oct 21
31 Mar 22
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 21 Mar 20 Mar 19 Mar 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Tyme earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 36.46M 36.46M 36.46M 36.46M 36.46M 36.46M
Cash burn (monthly) 23.69M (positive/no burn) 2.22M 2.17M 1.94M 1.92M
Cash used (since last report) 87.3M n/a 8.17M 8.02M 7.14M 7.06M
Cash remaining -50.84M n/a 28.29M 28.44M 29.32M 29.4M
Runway (months of cash) -2.1 n/a 12.8 13.1 15.1 15.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Oct 21 Michael Demurjian Common Stock Sell Dispose S No No 1 20,000 20K 24,178,546
5 Oct 21 Steve Hoffman Common Stock Sell Dispose S No Yes 1 78,125 78.13K 22,678,816
4 Oct 21 Michael Demurjian Common Stock Sell Dispose S No No 1.0011 20,000 20.02K 24,198,546
4 Oct 21 Steve Hoffman Common Stock Sell Dispose S No Yes 1 78,125 78.13K 22,756,941
27 Sep 21 Michael Demurjian Common Stock Sell Dispose S No No 1.12 20,000 22.4K 24,218,546
22 Sep 21 Carberry David Common Stock Buy Acquire P No No 1.03 50,000 51.5K 100,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

8.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 69 74 -6.8%
Opened positions 16 14 +14.3%
Closed positions 21 5 +320.0%
Increased positions 13 29 -55.2%
Reduced positions 23 15 +53.3%
13F shares
Current Prev Q Change
Total value 19.95M 51.83M -61.5%
Total shares 15.38M 20.12M -23.6%
Total puts 272K 426.5K -36.2%
Total calls 360.1K 595.7K -39.6%
Total put/call ratio 0.8 0.7 +5.5%
Largest owners
Shares Value Change
Vanguard 4.84M $6.09M -6.8%
Millennium Management 2.12M $2.67M +1209.2%
BLK Blackrock 1.92M $2.42M -66.9%
Healthcare Value Capital 1.5M $1.89M 0.0%
Geode Capital Management 828.95K $1.04M -35.5%
STT State Street 396.63K $500K -64.9%
HighTower Advisors 368.1K $464K +0.5%
Susquehanna International 328.82K $414K +53.3%
Ergoteles 317.8K $400K NEW
MS Morgan Stanley 246.02K $310K -11.2%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 1.92M -3.88M -66.9%
Millennium Management 2.12M +1.96M +1209.2%
STT State Street 396.63K -734.97K -64.9%
NTRS Northern Trust 185.61K -627.06K -77.2%
Geode Capital Management 828.95K -455.68K -35.5%
Nuveen Asset Management 0 -426.2K EXIT
Vanguard 4.84M -353.13K -6.8%
Ergoteles 317.8K +317.8K NEW
HRT Financial 227.54K +227.54K NEW
Qube Research & Technologies 187.59K +187.59K NEW

Financial report summary

AESErytech PharmaRafael
  • Our internal computer systems or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development program.
  • Use of social media could give rise to liability, breaches of data security, or reputational harm.
  • Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, financial condition or results of operations.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
Management Discussion
  • Net loss for the year ended March 31, 2021 was $28,979,000 or $0.22 per share compared to $22,001,000 or $0.19 per share for the year ended March 31, 2020. The increase in the net loss compared to the prior year was due to the non-cash expense variance of $7,560,000 in the fair value of the warrant liability, partially offset by non-cash gain of $2,229,000 on the warrant exchange and increased operating costs.  The increase in operating costs for the current year of $1,457,000 related to increased research and development costs of $4,075,000, partially offset by $2,618,000 decrease in general and administrative costs as explained below under “Operating Expenses.”
  • Cash used in operating activities for the year ended March 31, 2021 was $23,564,000 compared to $19,560,000 for the year ended March 31, 2020. See “Cash Flows” section below for further details.
  • Adjusted net loss, which excludes the change in fair value of warrant liability, amortization of employees, directors and consultants stock options and gain on warrant exchange, was $23,836,000 or $0.18 per share for the year ended March 31, 2021 compared to $19,560,000 or $0.17 per share for the year ended March 31, 2020. Adjusted net loss and adjusted net loss per share are non-GAAP measures. See “Use of Non-GAAP Measures” below for a reconciliation to the comparable GAAP measures.
Content analysis
H.S. sophomore Avg
New words: academic, accumulated, Additionally, AEs, agency, Ahmed, aid, area, began, begun, benchmark, biomarker, biopsy, bringing, CBR, chance, chemotherapy, classification, closeout, Compassionate, complexity, composition, comprehensive, concentration, corona, credit, cycle, DC, decline, Delta, deposit, displayed, distinct, diversification, diversify, DOR, efficiency, effort, encompassed, enhance, Evotec, expedite, experienced, extensive, facet, failed, fluctuate, focused, Foundation, franchise, gene, Georgetown, group, hold, hormonal, HR, identification, Impairment, individual, infection, inhibitor, institutional, interpretative, IP, issuer, iv, Joseph, landscape, line, located, maintenance, Maryland, maturity, mixed, MOA, MPS, municipal, objective, ORR, OS, outsourced, overlooked, oversee, parallel, pathway, PFS, PI, placement, preserve, probe, produced, professional, pronouncement, proper, quickly, recognition, reevaluation, refine, removal, Richie, salvage, sensitivity, simplification, sought, stop, surgical, susceptibility, timeline, translational, unacceptable, uncontrolled, unlock, Unrealized, untapped, variant, vi, vitro, Wainwright, Washington, widely
Removed: actively, adapting, added, administration, aim, allocated, America, arrangement, attempt, Barbara, Canaccord, capacity, care, carrier, Codification, compromising, computing, conference, Consistent, coverage, create, decision, distribution, downturn, encouraging, ending, enrolled, ESMO, European, examine, expand, expansion, federal, Food, Galaini, Genuity, hematological, Hoffman, hospital, impede, increase, insurance, joining, local, mechanism, mechanistically, mission, monitoring, Network, offer, opening, participated, predominately, principally, prioritization, racemetyrosine, reclassified, recurrent, regulate, regulator, reopen, Restated, safer, shortly, showing, size, Society, Steve, structurally, suggested, survival, underwriter, underwriting, underwritten, undistributed